Ivermectin for Cancer: Dr. William Makis Protocol Explained (2026 Guide)

Medically Reviewed by: Dr. Frank Yap, MD  |  Written by: OneDayMD Editorial Team  |  Last Updated: September 2026

Important Disclaimer: This article is for educational purposes only and does not constitute medical advice. Ivermectin, fenbendazole, and mebendazole are used off-label for cancer in the protocols described below; none is an FDA-approved cancer treatment. Do not self-medicate without bloodwork and physician supervision. Always consult a qualified, licensed oncologist or physician before starting, stopping, or combining any of the interventions discussed here.

Quick Answer (AI & Search Summary)

Dr. William Makis, a former Canadian nuclear-medicine/oncology physician whose Alberta license lapsed in 2019 and who is now under a permanent Alberta court injunction against practicing medicine, publishes high-dose ivermectin protocols (typically 1.0–2.0 mg/kg/day) combined with benzimidazoles (fenbendazole and/or mebendazole) for cancer, based on his own case reports rather than randomized trials. A handful of small, legitimate trials are underway or planned (NCT05318469, NCT07487805/ICONIC). Anyone considering this protocol should do so only under physician supervision, with baseline and ongoing liver/kidney monitoring.

Dr William Makis Ivermectin Protocol

Who Is Dr. William Makis

Dr. William (Viliam) Makis trained in nuclear medicine and radiology at McGill University and has authored more than 110 peer-reviewed publications, largely in imaging and oncology. He worked at the Cross Cancer Institute in Edmonton, Alberta, until 2016, and since 2023 has documented cancer cases treated with repurposed antiparasitic drugs — primarily high-dose ivermectin combined with benzimidazoles — on Substack and X, alongside a paid "cancer coaching" practice.

He also promotes the term "turbo cancer" to describe aggressive, rapid-onset cancers he links to COVID-19 vaccination — a colloquial phrase, not a recognized oncological classification, and one not supported by peer-reviewed epidemiological evidence linking vaccination to a distinct accelerated-cancer entity. None of this bears directly on whether ivermectin or benzimidazoles have anticancer activity, which is a separate scientific question addressed in the evidence sections below — but it is directly relevant to whether Dr. Makis is currently authorized to diagnose, treat, or provide individualized medical advice to patients, which readers should weigh for themselves.

Why This Protocol Matters in 2026

Dr. Makis says he has advised a large number of cancer patients using repurposed drugs since 2023, centering on high-dose ivermectin combined with fenbendazole and/or mebendazole, plus synergistic supplements and metabolic interventions, customized per patient. Because so many patients search for his specific dosing numbers — often without the surrounding safety context — this guide compiles those protocols alongside the regulatory notices, trial data, and case-level evidence needed to evaluate them.

Dr. Makis's Core Ivermectin Cancer Protocols (2025–2026)

Protocol Applicable Cancers Ivermectin Dose Benzimidazole Partner Key Add-Ons CEBM Tier
1. Standard Breast, colon, lung, prostate, melanoma, renal, gastric 1.0 mg/kg/day, daily, no breaks Fenbendazole 444–1000 mg/day OR mebendazole 1000 mg/day Berberine 500 mg 2–3×/day, CBD oil 100 mg/day Level 5 (expert opinion) + Level 4 (uncontrolled cohort)
2. Aggressive / "Turbo Cancer" Lymphoma, leukemia, pancreatic, GBM, sarcoma, triple-negative breast 1.5–2.0 mg/kg/day (some patients higher, under monitoring) Fenbendazole 1000 mg/day + mebendazole 1000–1500 mg/day (dual/triple) Methylene blue 50–100 mg/day, high-dose berberine, topical DMSO on accessible tumors Level 5 (anecdotal only)
3. Low-Dose Ivermectin + High-Dose Benzimidazole Ovarian, uterine, some breast (when high-dose ivermectin not tolerated) 0.5–1.0 mg/kg/day Fenbendazole 1000–2222 mg/day (continuous or 3-on/4-off) CBD/THC oils, berberine, liposomal curcumin Level 5 (anecdotal only)
4. Maintenance / Remission All cancer types after achieving NED 0.5–1.0 mg/kg, 3–5 days/week Fenbendazole 444 mg/day or mebendazole 500 mg/day Berberine, vitamin D 10,000–20,000 IU, liposomal curcumin Level 5 (expert opinion)

"Turbo cancer" is a colloquial term used by protocol proponents for aggressive, rapid-onset cancers — it is not a formal oncological classification. CEBM tiers reflect the Oxford Centre for Evidence-Based Medicine framework; Level 5 is the lowest tier (expert opinion/mechanistic reasoning or unverified anecdote), Level 1 the highest (randomized controlled trials).

Dr. Makis's Core Protocol Rules

  • Take ivermectin with a fatty meal for absorption.
  • Use only human pharmaceutical-grade 12 mg tablets — never veterinary formulations.
  • Monitor liver function tests (LFTs) and kidney function every 4–6 weeks throughout treatment.
  • Often combined with intermittent fasting or a strict ketogenic diet.
  • Topical DMSO combined with ivermectin on accessible tumors is claimed to accelerate local response (unverified beyond anecdote).
  • Milk thistle (silymarin) 300–600 mg/day is commonly used for hepatoprotection alongside the protocol; discuss with your physician before adding any supplement.

Broader Protocol Context

Ivermectin is one component of a wider seven-part framework Dr. Makis calls a Metabolic-Immune Cancer Protocol (see the companion Hybrid Orthomolecular Protocol article for the full mechanistic rationale):

  • Benzimidazoles: Mebendazole 200–1,500 mg/day or fenbendazole 222–1,000 mg 3–6×/week, depending on cancer grade
  • Vitamin D3: 2,000–50,000 IU/day, targeting a serum level around 80 ng/mL
  • IV Vitamin C: 1.5 g/kg, 2–3×/week for intermediate/high-grade cancers
  • Ketogenic diet: restricting carbohydrates toward a glucose-ketone index ≤ 2.0
  • Methylene blue: 50–100 mg/day in aggressive cases (drug-interaction risk — consult a physician)
  • Berberine: 500 mg 2–3×/day for metabolic synergy

Precautions: source medications from reputable pharmacies; avoid in pregnancy or with known contraindications; the supporting evidence is anecdotal and preclinical, with large controlled trials still lacking; never self-treat without medical supervision.

A close relative of this approach is the fenbendazole-centered Joe Tippens protocol, covered in depth in our Fenbendazole Joe Tippens Protocol guide.

The Ivermectin Dosing Controversy: Marik vs. Makis vs. Hope

There is no guideline-endorsed ivermectin dose for cancer, and prominent figures in the repurposed-drug community disagree sharply on what dose is appropriate — a dispute that became public in June–July 2026 on Substack. Rather than reproduce that exchange, the table below summarizes each school's position based on their published materials.

Source Typical Daily Dose Stated Ceiling Position
Dr. Paul Marik (Jun 2026) ~0.3 mg/kg/day starting; 0.2–0.4 mg/kg backbone 0.8–1.0 mg/kg/day only if needed Argues for the lowest effective dose; calls circulating high-dose protocols potentially toxic and not recommended, and argues the absence of large RCTs shouldn't be the only evidence considered.
Dr. Justus Hope / IMA (Jul 2026) 0.3 mg/kg/day (limited disease); 0.6 mg/kg/day (aggressive) Titrate toward 1.0 mg/kg/day if response is poor Publishes a similarly conservative lower band to Marik, with a defined titration pathway.
Dr. William Makis (2025–2026) Often 1.0 mg/kg/day for active solid tumors 1.5–2.0 mg/kg/day for high-grade/"turbo" cases Argues lower doses "don't work" for most active cancer cases, citing bioavailability concerns and pediatric brain-tumor/leukemia dosing precedents (see below) as evidence that higher doses are tolerated.
Journal of Orthomolecular Medicine (Sep 2024) 0.5 or 1.0 mg/kg/day, 3×/week, by grade 1–2 mg/kg/day (high-grade row) The peer-reviewed hybrid orthomolecular protocol co-authored by Marik and Makis; the highest published dose row is frequently cited by both camps.

Higher-dose proponents point to two pediatric precedents as evidence that aggressive dosing is tolerated: a small 2020 case series from MD Anderson and a Brazilian team using ivermectin 1 mg/kg/day in children with leukemia as young as 5 (two of three had a temporary remission), and a Johns Hopkins-sponsored pediatric brain-tumor trial (NCT02644291) using mebendazole up to 1,500 mg/day in children as young as 1. These trials establish that such doses have been used and monitored in specific pediatric protocols under close institutional supervision — they do not, by themselves, establish an equivalent adult oncology dose, since pediatric brain-tumor and leukemia dosing was developed for those specific populations and cancer types under trial-specific safety monitoring, not derived for general adult solid-tumor use.

Read more: Ivermectin Dosage for Cancer in 2026: Marik vs. Makis vs. Hope — What the Numbers Actually Are.

ASCO Clinical Notice & Regulatory Status

The American Society of Clinical Oncology (ASCO) Clinical Notice (May 2026) states that neither ivermectin nor fenbendazole has been established as safe or effective for cancer treatment in well-conducted randomized trials, and recommends against their use outside a registered clinical trial, citing unresolved questions about drug interactions, and the limits of the current evidence base.

Dr. Paul Marik has argued that relying solely on the absence of large RCTs gives an incomplete picture, and that preclinical, mechanistic, pharmacologic, and observational evidence should also inform whether these agents merit further study — a view that does not itself establish clinical efficacy, but supports evaluating the evidence across multiple levels rather than through RCTs alone. Dr. Makis, separately, has pointed to a small but growing number of registered oncology trials involving ivermectin, mebendazole, niclosamide, and melatonin as evidence of expanding institutional interest in repurposed drugs generally — a fair observation about trial registration volume, though registered trials in early phases are not themselves evidence of efficacy.

A September 2026 Substack post attributed to Dr. Makis claims that five named US institutions (Moffitt Cancer Center, Florida International University, Florida State University, Tampa General Hospital, and the University of Miami) have received a combined several million dollars in grant funding to study ivermectin in cancer. This figure is self-reported via screenshots on Dr. Makis's own channel; OneDayMD has not been able to independently verify these amounts against the institutions' own grant announcements or federal award databases (e.g., NIH RePORTER), and readers should treat the claim as unverified pending primary-source confirmation.

Should You Combine Mebendazole with Fenbendazole?

Preclinically, combining the two benzimidazoles produces combination-index values below 1 with structural analogues and has reduced xenograft tumor volume by 80–90% in some models. Clinically, the evidence is far thinner and largely indirect: a mebendazole-plus-temozolomide trial in glioma (EClinicalMedicine, 2022) supports the benzimidazole class generally, but fenbendazole itself remains formally untested in randomized trials, and the mebendazole+fenbendazole combination specifically has not been studied in a controlled human trial.

The real-world support for this combination consists of anecdotal reports from Dr. Makis's practice — for example, a 26-case-report Substack compilation describing pancreatic tumor shrinkage of 70–87% with a mebendazole-AM/fenbendazole-PM schedule, and a breast cancer case reaching no evidence of disease within 6 weeks on the triple combination with ivermectin. These are unverified, self-reported case reports (CEBM Level 5), not a controlled study, and should be weighted accordingly.

Risk: liver strain is a recognized concern with combined benzimidazole therapy — weekly LFT monitoring is advisable during combination use, alongside watching for gastrointestinal symptoms. See also our related guide, Fenbendazole vs. Mebendazole for Cancer.

The Hulscher et al. 2026 Cohort — and Its Expression of Concern

Hulscher et al. published a prospective observational cohort in Anticancer Research (Vol. 46, No. 6, pp. 3243–3255, 2026) evaluating a compounded ivermectin (25 mg) + mebendazole (250 mg) capsule sold by The Wellness Company, off-label, through a US telehealth channel.

Metric Reported Value
Total enrolled197 patients
Patients with ≥6 months follow-up122
Clinical Benefit Rate (CBR)84.4% (NED + regression + stable disease)
No Evidence of Disease (NED)32.8%
Tumor regression15.6%
Stable disease36.1%
Mild GI side effects25.4% (most continued treatment)

Formal Expression of Concern (2026)

Anticancer Research's editorial board issued an official Expression of Concern after publication, citing serious questions about the verifiability and statistical reliability of the underlying dataset and its ethical oversight. Separately, every listed author is affiliated with The Wellness Company (TWC) — the sole commercial seller of the exact compounded formulation the study evaluated — a conflict of interest not adequately disclosed at publication. OneDayMD itself has an affiliate relationship with The Wellness Company (disclosed in full below); we are flagging this conflict on both sides transparently rather than omitting it. As of this update, the study has not been retracted, but it remains observational, uncontrolled, based on self-reported outcomes, and should be read as hypothesis-generating only — not as confirmatory evidence of efficacy. CEBM Tier: Level 4 (uncontrolled cohort/case-series-equivalent), materially weakened further by the unresolved COI and EoC.

Ivermectin Combined with Checkpoint Inhibitors: Active Trials

Two legitimate, registered interventional trials are testing ivermectin alongside immune checkpoint inhibitors — a mechanistically distinct hypothesis from the anti-parasitic "direct kill" framing used in Dr. Makis's protocols, based on preclinical data suggesting ivermectin may help convert immunologically "cold" tumors "hot."

Trial Design Status & Results CEBM Tier
NCT05318469 (Cedars-Sinai/City of Hope) — ivermectin + balstilimab/pembrolizumab, metastatic TNBC Phase I/II, single-arm, 34 estimated enrollment 2025 ASCO data on 8 evaluable patients: 1 partial response, 1 stable disease, 6 progressive disease; median PFS 2.5 months; 4-month clinical benefit rate 37.5%. Investigators concluded the combination was "safe and well tolerated," but efficacy signal is modest (1 of 8 with a partial response). Level 2 (uncontrolled interventional cohort)
NCT07487805 (ICONIC, University of Florida) — ivermectin + checkpoint inhibitor, solid tumors Randomized Phase II, ~80 patients Not yet recruiting as of the last verified status update (July 2026); estimated start September 2026, estimated completion December 2027. No outcome data yet exists. Pending (will be Level 1–2 once reported, if randomized as designed)

Correction note: earlier versions of this article stated the ICONIC trial had "begun accruing." ClinicalTrials.gov's own status record instead shows it as not yet recruiting as of its last verified update — we've corrected that here and will update again once enrollment or results are posted.

Phase 2 RCT: Mebendazole in Stage 4 Colorectal Cancer

A phase 2 randomized controlled trial published in Life Sciences (2022) found that adding mebendazole to standard chemotherapy (bevacizumab + FOLFOX4) was well tolerated and associated with improved outcomes: overall response rate 65% vs. 10% at 12 weeks (p<0.001), and progression-free survival of 9.25 months vs. 3 months (p<0.001).

This remains the single strongest controlled-trial data point supporting benzimidazole use in cancer — but it is specific to mebendazole added to a defined chemotherapy backbone in colorectal cancer, not to the full ivermectin-benzimidazole combination protocol discussed elsewhere in this article. CEBM Tier: Level 1 (randomized controlled trial).

Real Patient Outcomes: A Case Reference Table

All cases below are drawn from Dr. Makis's 2025–2026 public testimonials (X @MakisMD and Substack). They are anonymized, self-reported, and not independently verified against medical records — outcomes may not be representative, and details Dr. Makis did not publish (such as full concurrent treatment history) are marked "not specified" rather than assumed.

Patient Diagnosis Prior/Concurrent Conventional Tx Reported Regimen Follow-Up Outcome CEBM Tier
53F, CanadaStage 2 triple-negative breast (7.8 cm)Not specifiedIvermectin protocol (dose not specified)7 months (Dec 2024–Jul 2025)Reported cancer-freeLevel 5
58M, CaliforniaRecurrent Stage 4 kidney cancerNot specifiedIvermectin protocol (dose not specified)10 weeksReported tumor regression ("dying tumors")Level 5
70M, MoroccoStage 4 lymphomaNot specifiedIvermectin protocol (dose not specified)2.5 monthsReported complete remissionLevel 5
39F, TexasStage 4 colon cancer, liver metsNot specifiedIvermectin protocol (dose not specified)4 monthsCEA fell from 441 to 21.9 (tumor-marker decline; not a confirmed radiologic remission)Level 5
42FStage 4 kidney cancer (lung/liver/shoulder mets)Not specifiedIvermectin protocol (dose not specified)1 yearReported NEDLevel 5
53F, UKStage 4 breast cancer (12 cm)Not specifiedIvermectin protocol (dose not specified)2 monthsReported 68% tumor shrinkageLevel 5
Adult F, 60 kgStage 3 ovarian cancerConcurrent chemotherapyIvermectin 12 mg/day (~0.2 mg/kg)2 monthsReported complete resolutionLevel 5
83FStage 3 follicular lymphomaNot specifiedIvermectin 1 mg/kg/day6 monthsReported near-total remissionLevel 5
54MRecurrent prostate cancerNot specifiedIvermectin 1.5 mg/kg/day4 monthsReported remissionLevel 5

Dr. Makis reports that among Stage 4 patients who follow his protocol rigorously, major response or NED rates "consistently exceed 65–70%." This figure reflects outcomes among patients under his direct, self-selected guidance — it is not a population-level efficacy estimate, has no control group, and should be interpreted with the same caution as the case table above.

Read more: Fenbendazole and Ivermectin Cancer Success Stories: 700+ Case Reports Compilation (2026 Edition).

Safety, Drug Interactions & Neurotoxicity

Ivermectin is a substrate and inhibitor of P-glycoprotein (P-gp/ABCB1), the efflux pump that helps keep the drug out of the central nervous system, and it is metabolized primarily via CYP3A4. This combination matters clinically for two reasons:

  • Neurotoxicity risk rises with dose and with P-gp/CYP3A4 interactions. At the well-established antiparasitic dose (roughly 0.2 mg/kg, single dose), CNS penetration is minimal in most people. At the 1.0–2.0 mg/kg/day doses used in these cancer protocols — five to ten times higher, taken daily rather than as a single dose — more drug is available to cross into the brain, and case reports of high-dose ivermectin toxicity describe confusion, ataxia, dizziness, and, in severe cases, seizures or coma.
  • Drug interactions compound the risk. Medications or substances that inhibit P-gp or CYP3A4 — including certain azole antifungals, some HIV protease inhibitors, macrolide antibiotics, verapamil, cyclosporine, and high-dose grapefruit — can raise ivermectin blood levels well beyond what the dosing table alone would predict. Conversely, CYP3A4 inducers (e.g., St. John's Wort, rifampin) may lower levels and reduce any intended effect. Patients on any interacting medication should have this explicitly reviewed by a pharmacist or physician before starting.

Because fenbendazole and mebendazole are also hepatically metabolized, combination use adds an independent hepatotoxicity risk on top of the neurotoxicity concern above — hence the repeated emphasis on LFT and renal monitoring every 4–6 weeks (more frequently, every 2–4 weeks, in patients with pre-existing liver disease).

Frequently Asked Questions

Is Dr. William Makis currently a licensed physician?
No, not in Alberta. His claimed Florida license status has not been independently confirmed by OneDayMD as of this update.

Has the Hulscher et al. ivermectin-mebendazole study been retracted?
No. It carries a formal Expression of Concern and an unresolved conflict of interest, but it has not been retracted as of this update.

Is the ICONIC ivermectin-checkpoint-inhibitor trial recruiting patients?
As of the last verified status check, it was listed as not yet recruiting, with an estimated September 2026 start.

Can I combine this protocol with Capecitabine (Xeloda) or other chemotherapy?
Fenbendazole and mebendazole share CYP2C9/CYP3A4 metabolic pathways with capecitabine and many other chemotherapy drugs, creating a theoretical interaction risk with no formal interaction study as of 2026. Disclose all medications to your oncologist and increase CBC/LFT monitoring frequency if combining.

What about cirrhosis or elevated liver enzymes?
High-dose ivermectin and benzimidazoles are hepatically metabolized. Pre-existing liver disease (cirrhosis, hepatitis, elevated LFTs) raises hepatotoxicity risk substantially; if used at all, this requires specialist supervision, lower starting doses, and LFT monitoring every 2–4 weeks.

Is ivermectin appropriate for multiple myeloma or leukemia?
Dr. Makis places hematologic cancers under his Aggressive/Turbo Cancer protocol. See our dedicated article, Ivermectin and Mebendazole in Lymphoma and Leukemia, for the specific case reports and their limitations.

Are there negative interactions with herbal supplements?
Patients have reported using liposomal vitamin C and D, vitamin K, curcumin, milk thistle, B-complex, turmeric, magnesium, krill oil, and NAC alongside this protocol without reported adverse events, but formal interaction data is lacking. Herbs that strongly affect CYP450 enzymes (St. John's Wort, high-dose grapefruit) may alter drug levels — disclose all supplements to your physician.

Does ivermectin help with parasites (non-cancer use)?
Yes — ivermectin is an FDA-approved antiparasitic. For parasitic infection, dosing is typically a single dose around 0.2 mg/kg or a short course, far lower than the cancer protocols on this page. Consult a physician for appropriate dosing.

What is the neurotoxicity risk with high-dose ivermectin, and how can it be reduced?
See the Safety, Drug Interactions & Neurotoxicity section above — risk rises with dose and with P-gp/CYP3A4-interacting medications, and can be reduced (though not eliminated) through careful medication review, dose caution, and monitoring for early neurological symptoms.

Updated Joe Tippens Protocol

A modified version of the Joe Tippens protocol — a synergistic combination of fenbendazole, ivermectin, and nutraceuticals — updated per the ivermectin/mebendazole protocol described in the Journal of Orthomolecular Medicine (2024) and the Hulscher et al. (2026) cohort discussed above:

Diet & lifestyle: a 2026 AACR-published study linked ultra-processed food intake to reduced survival after a cancer diagnosis; a 2026 BMJ study linked higher food-preservative exposure to higher overall and breast-cancer rates; and 2026 Nature Communications data linked insulin resistance to a roughly 25% higher risk across 12 cancer types. Favor a whole-food diet, minimize added sugar (below 25 g/day per BMJ 2023 guidance), and prioritize sleep and stress management.

Note: vitamin E was removed from the original Tippens protocol (per Joe Tippens, July 2020) due to interaction concerns with blood thinners.

Where to Get Ivermectin Safely

The Wellness Company's Ivermectin + Mebendazole combination (25 mg ivermectin + 250 mg mebendazole) is prescribed and supervised by licensed physicians, compounded at US-based pharmacies to pharmaceutical standards, and was the formulation evaluated in the Hulscher et al. (2026) cohort discussed above — including its Expression of Concern and disclosed conflict of interest, which we'd encourage you to weigh alongside the product's own marketing claims.

Important: do not purchase veterinary ivermectin formulations — concentration, inactive ingredients, and purity standards differ significantly from human pharmaceutical-grade preparations.

Affiliate Disclosure: OneDayMD has an affiliate relationship with The Wellness Company (referral code ONEDAYMD) and with Amazon Associates, and may receive compensation from purchases made through the links on this page. This does not change our editorial assessment of the underlying evidence, including the conflict-of-interest concerns discussed above.

Personalize This Guide with AI

You can ask an AI assistant to apply the evidence above to your specific situation — but always bring the answer back to your own oncology team before acting on it. Try prompts like these:

  • Claude: "Given this article's CEBM evidence tiers, summarize which claims about ivermectin and cancer have controlled-trial support versus anecdote-only support."
  • ChatGPT: "Explain the P-glycoprotein/CYP3A4 drug-interaction risk from this article in plain language for someone taking [list your current medications]."
  • Gemini: "Compare the Marik, Hope, and Makis dosing tables in this article and explain why they differ."
  • Perplexity: "Find the current recruitment status of NCT07487805 (ICONIC) and NCT05318469 and tell me if anything has changed since September 2026."

Conclusion

Cancer patients and families increasingly face situations where conventional oncology has exhausted its options, or where an aggressive cancer demands consideration of every reasonable avenue. Repurposed drugs like ivermectin, fenbendazole, and mebendazole represent a genuinely growing body of preclinical and observational interest — but as of September 2026, that interest has not yet translated into controlled clinical evidence of efficacy, the largest supporting real-world dataset carries a formal journal Expression of Concern and an unresolved conflict of interest, and the protocol's most visible proponent is under a permanent court injunction against practicing medicine in his home jurisdiction. None of that forecloses the underlying scientific question — registered trials are now underway to answer it properly — but it does mean this approach should be treated as complementary and investigational, not as a substitute for oncology care, and pursued only in genuine partnership with a licensed healthcare team who can weigh the benefit-risk ratio specific to your cancer type, stage, and overall health.

Follow us on Substack.

Important Disclaimers

  • This content is for educational purposes only and does not constitute medical advice. Ivermectin, fenbendazole, and mebendazole are used off-label for cancer. Always consult a knowledgeable, licensed physician.
  • Statements on this website have not been evaluated by the Food and Drug Administration. Content here is not a substitute for professional medical advice, diagnosis, or treatment.
  • The case reports presented reflect the self-reported experiences of other readers or third parties and are not independently verified. Your results may differ; do your own research and consult relevant medical professionals before attempting to self-treat any condition.
  • Cancer care is a team effort. Care should be supervised and coordinated by your primary oncologist, in addition to any integrative provider, primary care physician, and allied health professionals.
  • Integrating a repurposed drug does not mean rejecting conventional medicine — any such approach should complement, not replace, surgery, chemotherapy, radiation, targeted therapy, immunotherapy, or hormone therapy where indicated. See also our multi-modal cancer treatment strategy guide.
  • Caution: do not self-medicate without bloodwork and medical monitoring. Self-medication carries serious risks, including liver toxicity, neurotoxicity, and drug interactions.

References & Further Reading

  1. Juarez M et al. (2020). Antitumor effects of ivermectin at clinically feasible concentrations support its clinical development as a repositioned cancer drug. PLOS ONE.
  2. Elayapillai SP et al. (2021). Ivermectin inhibits growth and induces apoptosis of human ovarian cancer cells. International Journal of Oncology.
  3. Pinto-Díez C et al. (2022). Mebendazole plus FOLFOX4/bevacizumab in Stage 4 colorectal cancer. Life Sciences. doi:10.1016/j.lfs.2022.120522
  4. Sepulveda-Arias JC et al. (2022). Mebendazole + temozolomide in high-grade glioma. EClinicalMedicine. PubMed
  5. Hulscher et al. (April 2026). Real-World Clinical Outcomes of Ivermectin and Mebendazole in Cancer — Observational Cohort (197 patients). PubMed indexed.
  6. Yuan Yuan et al. (ASCO 2025). Phase I/II: Ivermectin + balstilimab in metastatic triple-negative breast cancer. Cedars-Sinai Medical Center.
  7. Makis W. Substack @MakisMD — Protocol updates and patient case reports (2023–2026).

PubMed / scientific

Clinical-trial / conference sources

Other scientific source

  • Baghli et al., 2024, Targeting the Mitochondrial-Stem Cell Connection in Cancer Treatment: A Hybrid Orthomolecular Protocol Journal article/PDF

Comments

Post a Comment

Popular posts from this blog

Ivermectin for Cancer Treatment: Protocols and Evidence (2026 Update)

Image
Ivermectin is a drug primarily used to treat parasitic infections, and it has attracted research interest for its potential biological effects in cancer models, particularly within integrative and experimental treatment contexts. Supporters point to hundreds of preclinical studies and case reports showing anti-tumor activity across multiple cancer types.  However, current mainstream oncology guidelines do not support ivermectin as a standard or evidence-based treatment for cancer, especially as a substitute for established therapies such as immunotherapy, targeted therapy, chemotherapy, or radiotherapy. So where does the truth lie? The answer is more nuanced than either side often suggests. Access to modern cancer care remains uneven globally. Advanced diagnostic testing, molecular profiling, and novel therapies are often more accessible in high-income healthcare systems or through comprehensive insurance coverage. In contrast, patients in lower-resource or impoverished settings m...
Read more

Fenbendazole and the Joe Tippens Protocol (2026): Evidence, Risks, and Current Perspective

Image
Medically Reviewed by: Dr Frank Yap, MD | Written by:     OneDayMD Editorial Team | Last Updated: September 2026 Introduction The Joe Tippens Protocol revolves around the off-label use of fenbendazole (a veterinary dewormer commonly sold as Panacur C or Safe-Guard) combined with various supplements for cancer. The Protocol has been gaining rapid interest over the past years following some  fenbendazole advanced cancer success stories . Joe Tippens popularized this approach after claiming it contributed to his remission from metastatic small-cell lung cancer in 2017. As of 2026, Joe Tippens remains alive and reports being cancer-free for over 8 years, continuing a maintenance version of the protocol. Fenbendazole is marketed for animals (e.g., Panacur C, Safe-Guard ) and has no regulatory approval for human cancer treatment . Evidence for anticancer effects is primarily preclinical or anecdotal , and clinical trials in humans are l...
Read more

Fenbendazole and Ivermectin for Cancer: A Case Series of Over 700 Patients (2026)

Image
Medically Reviewed | Last updated on July 2026. Anecdotal reports and preliminary studies suggest that ivermectin and fenbendazole, both antiparasitic drugs, may have potential anticancer effects when used alongside other treatments.  Many people immediately dismiss the potential of ivermectin and fenbendazole when they learn it is “horse or dog medicine”. That initial reaction is overcome when genuine human success stories are told including the lack of serious side effects. The testimonials you are about to read are from individuals who have bravely shared their experiences in the hope of inspiring and uplifting others. These are raw human accounts, unfiltered by gatekeepers—not peer-reviewed studies—but they offer insights that may be valuable to those searching for options. Repurposed Cancer Therapies Case Reports Explorer Interactive tracking dashboard compiling 766 reported case studies across 21 fields. Click any card to jump directly to its dedicated article ...
Read more

Fact Check: Can Ivermectin and Fenbendazole Help Treat Cancer?

Image
Ivermectin and fenbendazole, originally developed as antiparasitic drugs, are sparking hope in the fight against cancer, fueled by inspiring stories like those shared by actor  Mel Gibson on The Joe Rogan Experience , where he celebrated friends’ remarkable recoveries. While these medications aren’t yet standard cancer treatments, early research is uncovering exciting potential. Scientists are encouraged by promising lab studies and are calling for more clinical trials to confirm their effectiveness and ensure safe use in humans, paving the way for innovative, accessible therapies that could transform lives. Introduction and Context According to a January 22, 2025 fact-check article by AFP: "The anti-parasitic drugs ivermectin and fenbendazole are not currently recommended for cancer, but posts spread across social media touting the medications after actor  Mel Gibson claimed on the Joe Rogan Experience  that they cured his friends' cases of the disease. Oncology ex...
Read more

Top 10 Cancer Fighting Supplements: Evidence Based Literature Review (2026 Update)

Image
Quick Answer The supplements with the strongest human research behind them are vitamin D3 (paired with K2 and magnesium) , curcumin , omega-3 fatty acids , and green tea EGCG — each backed by multiple randomized controlled trials or meta-analyses, though results are mixed rather than uniformly positive. Melatonin looked promising in older, smaller trials, but the largest randomized trial to date found no overall survival benefit. No supplement replaces conventional cancer treatment, and a few — high-dose beta-carotene, vitamin E, and high-dose B6/B12 — have been linked to increased cancer risk in specific groups. Antioxidant supplements are generally discouraged during chemotherapy or radiotherapy unless a doctor directs otherwise. This is an educational overview, not personal medical advice — always loop in your oncology team before starting anything new. Disclosure: Some links in this article are affiliate links (including The Wellness Company and Amazon Associates). If ...
Read more

Dr. William Makis's Recommended Ivermectin Dosages for Cancer (2026)

Image
Last revised: July 2026 .  Integrative Oncology · Protocol Review A comprehensive synthesis of Dr Makis's clinical dosing regimens, benzimidazole combination strategies, the 2026 Hulscher observational cohort, pharmacokinetic rationale, safety monitoring requirements, and anonymised patient outcome data — presented with evidence grading. OneDayMD Editorial Team  |  Medically reviewed and updated  |  About Us Abstract Background: Dr William Makis MD (McGill Medicine; 110+ peer-reviewed publications) has treated cancer patients using repurposed antiparasitic agents since 2023, publicly documenting protocols and outcomes via Substack and X (@MakisMD). His approach centres on high-dose ivermectin combined with benzimidazoles and metabolic interventions, customised by cancer type and stage. Purpose: This continuously updated review synthesises Dr Makis's published p...
Read more

Exploring Ivermectin, Mebendazole and Fenbendazole as Aggressive Cancer Treatments: Research, Protocols, and Controversies (2026)

Image
Medically Reviewed by: OneDayMD Editorial Team | Evidence Synthesis & Safety Review | Last Updated: August 2026 Quick Answer Ivermectin, fenbendazole, and mebendazole are antiparasitic drugs with laboratory evidence of anticancer activity.  The pharmacological rationale is real and merits continued, properly controlled trial investment. Patients should discuss any interest in these agents openly with their oncology team rather than self-administering veterinary or compounded formulations.  This article separates the genuine research question from the unverified claims, and outlines what to discuss with an oncology team before considering any of these agents. Background: Ivermectin and the benzimidazole anthelmintics fenbendazole and mebendazole have attracted sustained public attention as repurposed anticancer agents, driven substantially by social media case testimonials and a small number of peer-reviewed mechanistic studies. Objective: To synthesize the precl...
Read more

Fenbendazole and Cancer: What the Science Really Shows (Evidence, Risks & Open Questions)

Image
Abstract Background:  Fenbendazole (FBZ), a benzimidazole anthelmintic approved for veterinary use, has attracted attention for potential anticancer activity based on laboratory findings and widespread anecdotal reports.  Objective:  To critically appraise the current evidence on fenbendazole and cancer using a peer‑review style framework.  Methods:  Narrative review of preclinical studies, publicly reported human case narratives, and safety signals, with emphasis on evidence hierarchy and translational limitations.  Results:  Preclinical data demonstrate antiproliferative effects via microtubule disruption and metabolic stress in vitro and in animal models. Human evidence is limited to uncontrolled case reports; no Phase I–III clinical trials or regulatory approvals for oncology exist. Safety data in humans are sparse, with hepatotoxicity signals reported.  Conclusions:  Fenben...
Read more

30 Best Alternative and Repurposed Cancer Treatments: Evidence Based Literature Review (2026 Update)

Image
Updated August 2026 · Evidence-Ranked Edition This article has been reorganised to rank all 30 integrative cancer interventions by the quality and quantity of available evidence — from randomised controlled trial data down to preclinical laboratory findings. Use this as a structured reference, not a treatment guide. Always consult a qualified healthcare professional before initiating any therapy. ⚠️ Medical Disclaimer: This content is for educational purposes only. Nothing in this article should be used as the basis for initiating, modifying, or discontinuing any cancer treatment without guidance from your treating oncologist or physician. The interventions described here are not approved cancer treatments unless explicitly stated. Diverse cancer hallmarks targeted by repurposed non-oncology drugs. Source: Nature 2024 Introduction Most mainstream guides to “alternative cancer treatments”—including the widely cited Mayo Clinic overview—fo...
Read more

Fenbendazole, Ivermectin and Mebendazole for Stage 4 Pancreatic Cancer: A Compilation of Case Reports and Mechanistic Insights (2026)

Image
OneDayMD  |  Integrative Oncology Review ISSN (Online) pending  •  Volume 1, Issue 1  •  Published: 10 August 2025  •  Last updated: 15 July 2026 Case Series & Mechanistic Review Compiled tumour marker responses, radiologic outcomes, and mechanisms of anti-cancer action across an international patient cohort DOI: pending  •  Cite as: OneDayMD Editorial Team. Antiparasitic Drug Repurposing in Stage 4 PDAC: A Compiled Case Series of 28 Patients. OneDayMD Integr Oncol Rev. 2025;1(1). Updated July 2026. Evidence Classification All case reports in this series represent CEBM Level 4–5 evidence (case reports and expert opinion). This compilation is hypothesis-generating. No randomised controlled trials of ivermectin, fenbendazole, or mebendazole for pancreatic cancer have been published as of July 2026. ...
Read more

Archive

Show more